

Northern Fondation du Nord Cancer Research pour la recherche Foundation en cancérologie



Rationale for Study

- Clinical observation: there can be adverse side effects from radiation treatment, "normal tissue reactions", that can occur in people for reasons that don't seem to be explained by traditional risk factors
- Published research: suggesting a genetic component to "radiosensitivity" which may be substantial
 - "...it has been estimated that as much as 80% of the variation in normal tissue reactions between patients cannot be accounted for by known factors and is likely to be genetic" Turesson, 1996

Determining who may be at risk to develop adverse effects from radiation therapy is important:

-improve patient care by modifying treatment for most sensitive

-current dose thresholds are set in order to limit toxicity in those who are most sensitive

Study Design

Establish an observational prospective cohort of men who attend the RCP for EBRT prostate cancer

- define outcome
- collect a sample for DNA analyses
- access chart and treatment data for important variables
- use this study as a platform, store samples for future research which will allow for the assessment of other cancer control outcomes

is E	
	BC - Hilfutoopharus Accopicus alida Terricities in Patents with Proving Crucer Pollowing Endiation (Scientific) 1
	Rosensch Ausseinner Jermän Derman, Deben Statemel, Son Adalmaler, Geby Sincord Michael Coulon, Mary Benick, Dr. J. Bowne and Dr. R. Basen
Trial Cance	Eider Polymorphisms Associated with Teolekies in Patients with Postate r Following Radiation Treatment
ToEs	nol Patients: Gall Clinical Research at ext. 2401
Paters prueta	s who will be seeving enternal basic radiation for intermediate to high risk to cancers as electer according to the following criteria.
alertes of tree	
Elgh	Handonically confirmed account edenocarcinoma
2	Eastern Cooperative Oncoloury Group (ECOG) Performance Scale 0-1:
ñ	Biomy proven present concer with Glearen score 7 or more.
	State 12 h/c or 13 disied state
	Stage 12 h/c or 13 clinical stage: Prostate Specific Antiger (PSA) of less than 42 within one mouth of study entry.
	Stage 12 h/c or 13 disidel stage. Process Specific Analyse (2004) of less than 40 within one mouth of study early. No enforce or nodel or distant metatomety.
	Stage 12 b/c or 13 clinical stage. Prostate Specific Antiger (154) of less than 63 within one month of study entry. No emission of nodal conductor metatrates; Patients may have been on bornoor thempy prior to, during or after occurrents;
005050	Stage 12: http://www.sectional.com/ Parsnare Specific Antiper (1984) of less than 62 within one mouth of study easily. No influence of nodal or distance metamone: Patients may have been on hormone thempty pilor to, during or after occurrence: No previses or concurrent investment enternet, tother has houldand bunk cell or No previses.
05058	Staging T2 Version 123 distributions and the state of
050000 0	Stage TO He of TS disined stage. Proceeds Specific Adapted 1998/01 (He is than 45 within one mouth of study entry. No orders or head or distance measurements). Patients may have been on between the head product of the distance or anteness in No provises or distance involve concerns, other than localized band will or separates of this correlevant, Life experisons, or kines of entry into study of the years or more.
65458 95458 9 Exclas	Singh TD, Vio et S. chick at regist horstone Specific Anging ONS of the set that Chickin one needs at outper chick hor inference or mold a chicken transmission. Their many how there is horstone thrompy their to, during outper constances is prefixed on the accession inference transmission. Other than leading to and chick parameters of the accession in the outper transmission of the specific outper laboration of the accession in the outper transmission of the specific outper- site entry of the specific outperson of the specific outperson of the specific outperson of the specific outperson of the specific outperson of the specific outperson outperson outperson outperson outperson.
6 5) 6) 7) 8) 7) 8) 7) 8) 7) 8) 7) 8) 7) 8) 7) 8) 7) 8) 70 8) 70 8) 70 8) 70 8) 70 70 70 70 70 70 70 70 70 70 70 70 70	Sogi Ta Vico 13 classic regio menure specific Arage (TSA) of less than Ca which one needs al study entry. The melanese are add or classer meansary. The melanese are add or classer meansary. Seg previous or concerns in melane scatters, other than leaded hand editor reparence of this concisions. The megacinese scatter of write that that do the period or needs the megacinese scatter of write that that do the period or needs. Here period or scatters of write that the that of the period or needs. Here period or scatters of write that the scatter of the period of the
65678 9 8088 9 8089 9 8098 9 8008 9 800 9 8000 9 800 9 900 900	Sogin Tally New The distribution segments and the set of the set o
65678 9 80878 9 8078 9 8	Sign Tables of the distribution of the second secon
·····································	Sogin Tan Yun (1) Shinka ange, Inoran Speeld Angerg (1994) den stran Ca white one moch ni moly easy, Tanan ang the anger and the stranger prior schedurg on all work anger Parent ng the dense in homesen function of the stranger of the schedule and all out particles of the schedures. The prior is an expression of the schedule anger of the schedule particles of the schedures. The prior is an expression of the schedule anger of the schedule in the prior is and the schedule anger of the schedule and all out particles of the schedule anger of the schedule anger of the schedule and prior prior is and been schedule and the schedule anger of the schedule anger and the schedule anger of the schedule anger for an express.
·····································	Sogin Tari Yuo Yi Shaka zago. Manana Yuo Yi Angala Yuo Yi Shaka za
·050050 · 0500500000	Sog ¹⁰ T21 (so ¹¹) Status argue, Sharpen Yushi, Angel (gel Jelen non-Christian con auch or in solven argu- phone may include and the solven arguest the solution of an and energy. Paterna and have been on between theory prior in solution (so and con- troperative an consense) in our rearry, took fast the solution (solution) theory prior is an and the solution (solution) and the solution (solution) theory prior is an and the solution (solution) and the solution (solution) theory prior is an advance. The reprior is an advance. The reprior is an advance in the solution (solution) and the solution (solution) in solution (solution) and the solution (solution) and the solution (solution) while are resonance, spatial, indication (space) and (solution) (Statisfies) are accounted repriored transformed.
· · · · · · · · · · · · · · · · · · ·	Sogin Tari Yuo Yi Shaka zago. Manan Syudia Angeo Yi Walion Kanan Garikita one machini sudy eany. Panina Kyudia Angeo Yi Walion Kanan Shaka
· · · · · · · · · · · · · · · · · · ·	Sug ² T2-10 (* 1) Status and Status and Status and Status and Status and Status and Status and Resentance or and Status and Status and Status and Status and Resentance of Status and Statu
· · · · · · · · · · · · · · · · · · ·	Sug ² T2-10 (* 1) Status and Status and Status and Status and Status and Status and Status and Resentance or and Status and Status and Status and Status and Resentance of Status and Statu





<u>EFFC</u> The <u>E</u> spanded <u>E</u> volutie Cancer <u>Ender</u> <u>Composite</u>
This guestionsame is disregated to insteam O satility at (the source is publicly and cancer. In the public the neuronal cancer measurement, it is important that you applicables to ready and compression. Resembler: I've with at medical records, coloradors and takes the survey dischip conductant.
Suly) Darighan ene inn shan newy onganik. Madi, Deg. Sue

The sector is a single to instance (seek y club more is public to be to seek the sector is a single to sector (seek y club more is public to be over more instance). The sector is a single sector is a single sector is a single sector is a single under the sector is set of the sector is set of the sector is here to be set of the sector is set of the sector is here to be specified in the sector is set of the sector is the club specified in the sector is a set of the specified in the sector is here to be specified in the sector is the club specified in the sector is the sector	name" in the part of the new possible index density. It is expected to they as well associates to actively and respectively. The second		<u>EPIC</u> The <u>E</u> spanded <u>B</u> rowints Cancer Judes <u>C</u> omposite
Neeripting	Neerlysted	gastion 1 gastion	bop as get the next accurate nearannexit, it is reporter that you an country and comparish. as with at nearant records, information contained within the servery of
Date of Neds (spinse) WeskVesVes	Dan effekt (spinel) Meek. De		
		Dentfield	(quinal) likelNeYee



1) Large sample in a well-defined patient population

- Treatment (exposure) to use a consistent dose (76 Gy in 38 fractions- 38 days of treatment M-F~ 8 weeks)
- Limit other factors that may complicate the relationship between genotype and toxicity

Regional Cancer Program Support Programme regional de cancérolog Support

ETIC - Polymorphisms Associated with Toxicities in Patients with Prostate Cancer Pollowing Radiation Treatment

Clinical Research Associates: Principal Investigators: Jenniler Dumont, Debra Bertrand, Sue Arkilander, Cathy Simeoni Michael Conlon, Mary Bewick, Dr. J. Bowen and Dr. R. Bissett

<u>Trial Title:</u> Polymorphisms Associated with Toxicities in Patients with Prostate Cancer Following Radiation Treatment

To Enrol Patients: Call Clinical Research at ext. 2401

Patients who will be receiving external beam radiation for intermediate to high risk prostate cancers are eligible according to the following criteria:

Study Process: Patients will be given an information package containing a summary of the study, a consent form for access to medical records and a saliva sampling kit for genetic analysis. In addition to standard clinical toxicity assessment, quality-of-life will also be assessed by the patient using the EPIC questionnaire (one questionnaire given at beginning of treatment, one at end of treatment (last day) and one mailed to patient after 2 years). The relationship between genetic variation and the development of toxicity in these men will be determined.


Eligibility:

- 1) Histologically confirmed prostate adenocarcinoma;
- 2) Eastern Cooperative Oncology Group (ECOG) Performance Scale 0-1;
- 3) Biopsy proven prostate cancer with Gleason score 7 or more;
- 4) Stage T2 b/c or T3 clinical stage;
- 5) Prostate Specific Antigen (PSA) of less than 40 within one month of study entry;
- 6) No evidence of nodal or distant metastases;
- 7) Patients may have been on hormone therapy prior to, during or after treatment;
- No previous or concurrent invasive cancers, other than localized basal cell or squamous cell skin carcinoma;
- 9) Life expectancy at time of entry into study of five years or more.

Exclusion:

- 1) Prior pelvic external beam radiation;
- 2) Prior prostate brachytherapy;
- 3) Prior bilateral orchiectomy;
- 4) Previous or concurrent cytotoxic chemotherapy for any cancer;
- 5) Previous prostatectomy;
- 6) Previous cryosurgery or high intensity focussed ultrasound (HIFU) for prostate cancer,
- 7) Life expectancy less than 5 years;
- 8) Connective tissue disease.





Acute Toxicity (occurring during or within weeks of treatment)

-occurs in rapidly proliferating tissue (epithelial cells in the alimentary tract), tend to cause inflammation, often reversible -in radiation for prostate cancer involve bowel and urinary symptoms

-might disturb the usual application/radiation dose

- We have enrolled 73 men into the study
- 52 men had completed a baseline and end of treatment questionnaire (and therefore we have "acute" toxicity information)

Defining Outcomes

..... "Clearly, prospective scoring has potential advantages as a means of obtaining toxicity data because of the potential for reporting bias with retrospective collection. Prospective collection of patient-reported toxicity scores would be even more ideal, and we recommend that this be incorporated into *future studies*".... Damaraju et al. Clin Can Res 2006;12(8) April 15

EPIC Questionnaire

F	D	π	r	ŧ.
с.	г	1	<u> </u>	6

The Expanded Prostate Cancer Index Composite

This questionnaire is designed to measure Quality of Life issues in patients with Prostate cancer. To help us get the most accurate measurement, it is important that you answer all questions honestly and completely.

Remember, as with all medical records, information contained within this survey will remain strictly confidential.

Today's Date (please enter date when survey completed): Month Day Year


Name (optional)


Date of Birth (optional): Month Day Year


Copyright 2022. The University of Michigan All rights reserved.

- Comprehensive tool to evaluate patient function and bother after prostate cancer treatment
- Instrument development was based on advice from an expert panel and prostate cancer patients, which led to expanding the 20-item University of California-Los Angeles Prostate Cancer Index (UCLA-PCI) to the 50 item Expanded Prostate Index Composite (EPIC)
- EPIC assesses disease-specific aspects of prostate cancer and its therapies and comprises four summary domains (Urinary, Bowel, Sexual, and Hormonal)
- Provides a measure of general satisfaction from care
- The tool also includes the Medical Outcomes Study SF-12 (quality of life on both physical and mental dimensions), and the AUA (American Urological Association) scale for urinary dysfunction


Page 6 BOWEL HABITS The next section is about your bowel habits and abdominal pain. Please consider ONLY THE LAST 4 WEEKS. 22. How often have you had rectal urgency (felt like I had to pass stool, but did not) during the last 4 weeks? More than once a day	Do Not Marik in This Space 421	 Missing values (need 12 of 14 to score) Scoring algorithm Calculate Summary Bowel Scores 	
About once a week4		- 0 (poorest) to 100 (best)	
Rarely or never		Five or more	
More than once a day 1		More than once a day 1	
About once a day2		About once a day2	
More than once a week	43/	More than once a week	48
About once a week4 Rarely or never		About once a week4	
		Rarely or never 5	
24. How often have you had stools (bowel movements) that were loose or liquid (no form, watery, mushy) during the last 4 weeks?		29. How big a problem, if any, has each of the following been for you? (Circle one number on each line) No Very Small Small Moderate Big	
Never 1		<u>Problem Problem Problem Problem Problem Problem</u> a. Urgency to have	
Rarely 2		a bowel movement 0 1 2 3 4	49
About half the time	44/	b. Increased frequency of	
Usually		bowel movements 0 1 2 3 4	50
Always5		c. Watery bowel movements 0 1 2 3 4	51
25. How often have you had bloody stools during the last 4 weeks?		d. Losing control of your stools 0 1 2 3 4	52
Never		e. Bloody stools 0 1 2 3 4 f. Abdominal/ Pelvic/Rectal pain 0 1 2 3 4	53 54
Rarely 2		1. Abuomina/ Pelvion etai pain 0 1 2 5 4	34
About half the time	45/	30. Overall, how big a problem have your bowel habits been for you during the last 4 weeks?	
Usually4		No problem 1	
Always5		Very small problem2	
		Small problem3 (Circle one number)	55
		Moderate problem 4	
		Big problem5	1
		EPIC 2.2002 Copyright 2002. The University of Michigan. All rights reserved.	1
EPIC 2.2002 Copyright 2002. The University of Michigan. All rights reserved.	1		1








Morton et al (2010), intermediate cancer risk, n=111 Mean=95.2, sd 7.4



Mean difference=-16.4, sd 17.6

Inter-individual variation




n=22, no decrease in Bowel HRQOL

-0.4 (-0.8) sd 6.0

-25.9 (-21.0) sd 13.25

Molecular Genotyping




differences (SNPs) occur in


humans

From Genes to Proteins

Single nucleotide polymorphisms



Single nucleotide nolvmornhisms



Single nucleotide polymorphisms

- SNPs refer to normal differences in nucleotide sequence between individuals
 - some genes have multiple SNPs
 - SNP frequencies differ among populations (race/ethnicities)
 - homozygous or heterozygous for a particular SNP
 - some SNPS code for different amino acids and may therefore modify protein function
- SNPs are associated with disease incidence or susceptibility, and outcome from treatment

Normal Tissue Toxicity

 Radiosensitivity is suggested to be a complex, polygenic trait which results from the interaction of a number of genes in different cellular pathways Cellular pathways in normal tissue toxicity:

- DNA damage induction and repair
- Apoptosis
- Pro-fibrotic and inflammatory cytokines
- Endogenous antioxidant enzymes
- General metabolism and homeostasis

DNA Repair SNPS in study

- XRCC3 (DSBR-HRR)*[radiotoxicity/sensitivity]
 - Threonine->Methionine
- Lig4 (DSBR-NHEJ)*
 - Aspartic acid->Aspartic acid
- XRCC1 (BER)- [treat resp breast cancer]
 - Arginine->Glutamine

• ERCC1 (NER)- [platinum drugs]

- Glutamine->Lysine
- ERCC2
 - Lysine->Glutamine
- ERCC5
 - Aspartic acid->Histidine

What are the odds ratios (ORs) using the at-risk genotypes and our case-control designations?

XRCC3	Case	Control	OR (95% CI)
0 (ref)	24	20	1.0 ref
1	6	2	2.5 (0.45-13.78)

LIG4	Case	Control	OR (95% CI)
0 (ref)	5	9	1.0 ref
1	25	13	3.5 (0.96-12.48)

XRCC1	Case	Control	OR (95% CI)
0 (ref)	2	4	1.0 ref
1	28	18	3.1 (0.52-18.78)

ERCC1	Case	Control	OR (95% CI)
0 (ref)	16	16	1.0 ref
1	14	6	2.3 (0.72-7.60)

ERCC2	Case	Control	OR (95% CI)
0 (ref)	13	13	1.0 ref
1	14	8	1.8 (0.55-5.58)

ERCC5	Case	Control	OR (95% CI)
0 (ref)	25	20	1.0 ref
1	3	1	2.3 (0.72-7.60)

XRCC3	Case	Control	OR (95% CI)
0 (ref)	24	20	1.0 ref
1	6	2	2.5 (0.45-13.78)

+

LIG4	Case	Control	OR (95% CI)
0 (ref)	5	9	1.0 ref
1	25	13	3.5 (0.96-12.48)

+

XRCC1	Case	Control	OR (95% CI)
0 (ref)	2	4	1.0 ref
1	28	18	3.1 (0.52-18.78)

+

ERCC1	Case	Control	OR (95% CI)
0 (ref)	16	16	1.0 ref
1	14	6	2.3 (0.72-7.60)

+

ERCC2	Case	Control	OR (95% CI)
0 (ref)	13	13	1.0 ref
1	14	8	1.8 (0.55-5.58)

+

ERCC5	Case	Control	OR (95% CI)
0 (ref)	25	20	1.0 ref
1	3	1	2.3 (0.72-7.60)

Variants	Variants Case		OR (95% CI)
0	0	1	
1	2	8	1.0 ref
2	5	3	7.5 (0.92-61.05)
3	12	4	13.5 (2.01-90.69)
4	6	4	7.9 (1.10-56.12)
5	1	0	

P(trend)=0.02

Variants	Case	Control	OR (95% CI)
0-2 (ref)	7	12	1.0 ref
3-5	19	8	4.0 (1.17-14.05)

Other factors that may complicate the relationship between genotype and toxicity

- 1) physics (total dose, dose per fraction and volume irradiated, irradiation site and dose inhomogeneity)[n=27 %rv>7000cgy;imrt]
- 2) additional treatment (use of concomitant chemotherapy or surgery)
- 3) patient characteristics (age (72), use of cigarettes (51%), haemoglobin level and co-morbid conditions such as diabetes (14%), hypertension (48%) and connective tissue diseases)

Opportunities


- The study provides a rich source of data that may help improve patient care:
 - Satisfaction from care
 - Standardized measures of HRQOL at early and late time points
 - Genomics as a potential clinical tool
 - Future cohort follow-up to assess cancer control outcomes (FFBF, overall survival)

• End of Original Slides

Genotyping

- Saliva was collected using Oragene DNA self-collection kit-Disc format (DNA Genotek Inc, Ottawa, ON)
- Referenced validated Taqman assays and ABI PRISM 7900HT determine genotypes





Criteria for choosing SNPs

- Candidate selection
 - suggested role in normal tissue toxicity in previous studies
 - important in the DNA repair pathway (defined as "critical" to the efficient functioning of a pathway)
 - suggested to modify protein function as they change the amino acid sequence
 - available validated assay